Few diagnostics stocks have staged a stranger rebound than Myriad Genetics. Last quarter the company cut its full-year revenue outlook by roughly $90 million at the midpoint, suspended its adjusted EBITDA guidance and announced a restructuring. The stock then nearly doubled. When Myriad reports third-quarter results after the close on November 4, the question is whether that rally anticipated a genuine stabilization in reimbursement or simply reflected relief that the worst news was already out.

The Street is not asking for much. Consensus calls for a loss of 25 cents a share, which matches the adjusted loss Myriad posted in the second quarter, on revenue of $188.6 million. That would be down 8.3% from a year ago and slightly below last quarter's $190.7 million. Management now guides to 2026 revenue of $770 million to $790 million. With about $391 million booked in the first half, the low end of that range implies roughly $189 million a quarter for the rest of the year. The quarterly consensus sits just under that pace, so analysts appear to be leaning toward the bottom of the range rather than trusting the midpoint. The full-year consensus of about $859 million still reflects the old outlook and looks out of date. The quarterly number is the more useful bar.

The core issue is price, not demand. Volumes were healthy last quarter. MyRisk hereditary cancer testing grew 10%, with the best quarter in three years among patients without a cancer diagnosis, and GeneSight reached a record of more than 40,000 ordering clinicians. Those gains were overwhelmed by a 9% drop in average revenue per test, and by a 15% drop in the cancer care segment. Payers had stepped up prior authorization demands, medical record requests and automated denials on MyRisk. Management admitted it should have engaged with insurers sooner. It also said the new guidance assumes no improvement in revenue per test from second-quarter levels. That conservatism creates a fair test. If revenue per test holds flat or ticks up while MyRisk volume keeps growing at a high single-digit or double-digit pace, the reset looks adequate and possibly cautious. Another step down would suggest payer pressure is still building and that the lowered range may not be low enough.

Several secondary items matter too. The second quarter absorbed about $11 million of lower prior-period collections, including a $4 million write-off of aged GeneSight receivables. A cleaner quarter without similar charges would help gross margin move toward the reduced 66% to 67% target. Prenatal volume fell 9%, and the recovery there has been pushed out repeatedly, so any sign that the newly launched FirstGene screen is gaining traction would be welcome. Liquidity has slipped from $225 million to about $190 million over two quarters, which makes cash burn worth monitoring. Investors will also want details on the ASCEND efficiency program and the portfolio review, including whether any divestitures are taking shape, even though management says most of the benefits arrive in 2027 and beyond.

The setup is unusual. Sentiment has swung from mildly bullish before the last report to clearly bearish now, yet the stock has gained 94% against a 2.8% rise in the S&P 500. At $6.02 it trades well above its 200-day moving average of $4.62 and within a few cents of its post-earnings high of $6.07, close to a breakout attempt. That leaves less margin for error than the cautious estimates suggest. A large part of the recovery from the $2.74 low is already priced in.

Ultimately, this report hinges on whether realized pricing has found a floor. Myriad has shown that clinicians still want its tests. It now needs to show that insurers will pay for them at stable rates. Until that happens, the company's growing volumes will not translate into a credible path back to profitability.